Adaptogenic Mushrooms (Reishi, Cordyceps, Chaga)

Immune support is the trio's best-evidenced claim, and reishi carries it. Chen 2023 randomized 135 healthy adults to 200 mg/day reishi beta-glucan for 84 days and reported NK-cell counts up 19.5 percent, NK cytotoxicity up 83.1 percent, and IgA up 10 percent versus placebo. The Zhong 2019 meta-analysis of 23 cancer RCTs found raised CD3 and CD4 but no significant NK effect, so the immune story is real yet inconsistent across populations. Cordyceps and chaga immune data are mostly preclinical. Score the marker shift, not a hard clinical-outcome claim, and pick one immune endpoint before starting.

The adaptogen label rests mostly on tradition and fatigue endpoints rather than dedicated stress-hormone RCTs. The strongest human anchor is Tang 2005, where 132 neurasthenia patients on reishi polysaccharide for 8 weeks reported a 28.3 percent drop in fatigue and improved well-being versus placebo. That maps onto perceived stress resilience more than to a measured cortisol effect. Cordyceps adds an energy-and-recovery angle, and centuries of TCM tonic use give the class a plausible, low-risk resilience role. The honest read is moderate: a felt, subjective benefit in tired or run-down people, not a validated anxiolytic. Define a stress or fatigue scale and judge by that.

Reishi is the classic evening mushroom, and the human signal is indirect but real. In Tang 2005, neurasthenia patients on reishi polysaccharide reported better well-being and less fatigue, outcomes that overlap with sleep and daytime restoration. Dedicated polysomnography RCTs in people are thin, so most sleep evidence is animal or anecdotal. The practical pattern users report is easier wind-down and steadier sleep over a few weeks rather than an acute sedative hit. Cordyceps and chaga have no sleep role. Treat reishi as a gentle, slow nightly tonic, track a simple sleep-quality rating for 8 to 12 weeks, and stop if nothing shifts.

Cordyceps owns this use case, and the honest finding is modest. Chen 2010 gave healthy older adults Cs-4 for 12 weeks and saw a 10.5 percent rise in metabolic threshold and 8.5 percent in ventilatory threshold, with no change in VO2 max. The widely cited VO2 max gain comes from Hirsch 2017, but that was a multi-mushroom blend, so the effect cannot be credited to cordyceps alone. The Jedrejko 2026 review calls the human ergogenic evidence investigational. Expect small submaximal gains in less-trained people, not a meaningful edge for trained athletes.

Antioxidant capacity is the headline chaga claim and the weakest in humans. The Ern 2023 review documents strong antioxidant and anti-inflammatory activity from chaga polysaccharides, triterpenoids, and phenolics, but the evidence is cell and animal, not clinical. Reishi triterpenes and cordyceps add to the class antioxidant rationale mechanistically. No quality human trial shows a durable oxidative-stress benefit you would feel. This subrating sits at the midpoint because the mechanism is plausible and consistent across the class, while human outcome proof is absent. If antioxidant status is the goal, measure a marker like oxidized LDL or F2-isoprostanes and treat the supplement as unproven until your own number moves.

Daytime energy and reduced tiredness are among the more believable felt effects of this class. The human support is the Tang 2005 reishi trial, where neurasthenia patients reported a 28.3 percent drop in fatigue, plus the Chen 2010 cordyceps trial showing submaximal-threshold gains that translate into less perceived effort during activity. Chaga adds nothing here. The effect is real but modest and takes weeks to appear rather than acting like a stimulant, so it suits people who are run-down or recovering rather than those seeking an acute lift. Track a simple daily energy rating and judge cordyceps and reishi by that, stopping if nothing shifts in 8 weeks.